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1. Introduction 
Microbubble technologies have recently gained acceptance as radiological molecular 
imaging or perfusion agents. These intravenous ultrasound contrast agents consist of gas-
filled microspheres stabilized by a ‘shell’ layer which interfaces with a surrounding solvent 
pool. Development in the form of encapsulation with complex biocompatible polymer shell 
consisting of proteins, lipids and surfactants has improved their stability and half-life 
significantly. These shell modifications have optimised the mechanical index of 
microbubbles, making them more resistant to compression rather than expansion.  
The relatively inert nature of microbubbles contributes to a favourable safety profile and 
‘stealth’ delivery profile. These indolent properties of microspheres are fundamental to their 
ability to function as targeted delivery vehicles for potential therapeutic modalities. Their 
small size (1-8 micrometre) enables unobstructed diffusion between the vascular and 
capillary compartments. Complete isolation of the active therapeutic components from 
normal native tissues and liberal exposure to the target disease tissue is the panacea of drug 
delivery.  
Incorporation of lipopolysaccharide ligands adhering to selective cell surface epitopes, to 
the microbubble surface interface, is the principal method by which these vehicles can be 
precisely targeted. Selective bioactive material delivery into the target cell significantly 
improves therapeutic efficacy and can completely negate the adverse side-effects.  
Externally applied focused ultrasound directed at the ligand bound microbubbles and target 
cells complex is the crucial final step ensuring optimal delivery. Application of sonication 
results in the oscillation followed by destruction of the bubbles and liberation of the 
bioactive compound; the high intensity focused acoustic energy disrupts the microbubbles. 
Passage of the active product into the intracellular space is facilitated through cellular 
sonoporation, at least in part as a result of acoustic cavitation of the target cell’s membrane.  
It has been demonstrated that microbubble technology can accommodation active 
constituents, hence be ‘drug loaded’. Microbubble delivery technology has been utilised as a 
feasible drug delivery modality for gene therapies, cytotoxics, drugs and dyes. Co-
administration of the microbubbles with the active product, without drug loading, has also 
been utilised to improve targeted drug delivery.  
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The premise of the clinically applicable microbubble delivered therapeutic agent delivery is 
an attractive proposition, but the clinical experience is still limited. Establishing the clinical 
benefits of microbubble technologies in the field of diagnosis has opened the door to a 
precise and accurate drug delivery vector. The proliferation in interest surrounding 
microbubbles has yet to meet its climax; the scientific, translational and clinical challenges of 
this exciting technology are still to be fully elucidated.  
In this chapter we will consider the current understanding of the elucidated theory 
underlying this technology, and the potential clinical applications with drug and gene 
delivery. We also endeavour to summaries uncertainties and controversies.  
2. The evolution of microbubble 
High-intensity focused ultrasound is used routinely for the lithotripsy of the renal calculi. 
The ablation of the solid tumours and regions of tissue with high-intensity focused 
ultrasound is a less proven application. Since the inception of the microbubbles their 
application has grown exponentially with incremental advances in their formulations 
(Tinkov et al., 2009).  
The dawn of microbubble technologies began with an innocuous in vitro observation that 
simple agitated saline enhanced ultrasound signal. This observation was demonstrated in 
cardiological and aortic ultrasound echocardiogram signal within the aortic root and 
chambers of the heart (Gramiak & Shah, 1968). The first generation microbubble contrast 
ultrasound agents were largely only applicable to diagnostic situations where additional 
opacification of the myocardium and coronary vessels is was necessary. The limited 
spectrum of clinical application was the result of the inherent characteristics of these first 
generation microbubbles agents (Kaul. 1997).  
The fragile in vitro composition of these microbubbles is the result of unstable gas fluid 
interface and large bubble size. First generation microbubble agents consist of simple air 
bubbles dispersed in aqueous solution with an absence of a stabilising shell. The large 
bubble diameter ensured these agents do not to pass through the small capillaries, including 
the intrapulmonary circulation. This with combined with the exceptionally short life-span 
beds means that these first generation agents will never become detectable in within the left 
ventricle after intravenous injection (Kaul. 1997). 
Later generations of microbubble agents have increasingly sophisticated colloidal 
gaseous/aqueous shells, which results in enhanced stability characteristics. The improved 
modalities of the later generations of microbubbles contrast dyes are now are recognised 
part imaging adjunct. The smaller size distribution of second generation enabled 
transpulmonary passage. Following intravenous administration of this generation of 
microbubble agents with stabilised solvent-gaseous interface they can become detectable 
within the left heart chambers. This generation is limited by unstable gaseous cores. Despite 
the composite shells the air cores have a tendency to dissolve in the blood within minutes. 
Subsequent generations replaced these highly soluble gaseous air nucleuses to overcome 
this inherent characteristic which limited their half-life (Voci et al, 1994). 
Third generation microbubble compounds contained physiologically inert gas cores 
propagated their stability almost tripling half-life to at least 15 minutes. This generation has 
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extended the application of microbubble agents to any ultrasound amenable organs. Further 
manipulation of the agents will ensure further broadening of their scope of application 
(Tinkov et al., 2009). 
The trends in the developments in later generations of microbubbles agents have moved 
away from the diagnostic efficacy and towards therapeutic modalities with drug carrying 
capacities. Precise formulation and engineering is necessary to ensure the efficacious 
delivery of specific active products (Pitt et al., 2004).  
3. Drug targeting 
The essential facet of effective targeted drug delivery is the ability to improve the 
therapeutic efficacy and minimise the quantity of circulating application of unbind active 
drug. The implications of this include reduction of the adverse effects and a significant 
minimisation of the effective required dosage necessary. The second property is 
paradoxically essential for the premise of the drug-loaded microbubbles to be efficacious 
because of the shell drug-loading capacity is limited. Because of this, only extremely potent 
agents with a low toxicity threshold would be amenable to this form of delivery. 
Poly/oligonucleotide gene therapy, cytotoxic, steroid, antimicrobials and active protein 
compounds may benefit from microbubble compounds. 
It is necessary to expose the systemic circulation to the active compound bound to 
microbubble to ensure close enough proximity to the target organ. It is undeterminable and 
unpredictable to accurately the proportion of the active product liberated by focused 
ultrasound destruction at the desired target organ site. Of the remaining non-utilised 
microbubble complexes some will be eliminated or be dispersed remotely from the target 
organ. Well perfused organs, such as the renal (Koike et al 2005) and myocardial (Vannan et 
al 2002; Shohet et al 2000) systems will witness higher microbubble agent concentrations, 
making an ultrasound liberation of the active products more effective. Organs with inferior 
blood perfusion levels may not witness the necessary concentrations to make the targeted 
ultrasound microbubble destruction efficacious. Hence, the extent of blood supply alone 
may significantly ameliorate any possible projections of the efficacy of targeted therapeutic 
microbubbles (Tinkov et al., 2009).  
The bodies’ innate mechanisms can be harnessed to preferentially channel microbubbles to 
the desire target tissues. This approach of passive targeting relies on the innate non-specific 
macro- or microcellular characteristic. Reliance on these non-specific in vitro mechanisms 
means that these agents will be amenable to the influences of pharmacodynamics forces. 
Two relevant mechanisms include the particle clearance, aspects of the innate and even 
adaptive immune systems. An example of such a modality includes the effects of immuno-
receptive microbubbles typically include those with phospholipid microbubbles containing 
phosphatidylserine and those which possess polymer-shells. Phagocytic immune white 
blood cells consume these antigenic microbubbles and convey these microbubbles to sites of 
active inflammation. Spontaneous non-macrophage mediate passive accumulation of 
ligand-containing microbubble agents via pathological or physiological enhancement in 
endothelial permeability and then retention has been found not to be possible (Bloch et al., 
2004). 
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Active molecular targeting is essentially the incorporation of intentionally designed 
microbubble manipulations to ensure preferential affinity to the desire target tissues. Cell 
targeting can be achieved with a series of complementary immunoliposome (Siwak et al., 
2002) and nanoparticle ligands (Shi et al., 2007) to specific cell surface receptors attached to 
the microbubble shells. Isolated or preferential expression of particular diseased cell-specific 
receptors on their surface provides a means by which targeting discrimination can be 
achieved. Complex formation between the complementary cell surface and attached 
microbubble shell protein ensure both selectivity and persistence of the vector to the target. 
A major area of research has been into the active molecular targeting of microbubble agents 
are that they wholly reside within the intravascular compartment and will only come into 
contact with potential target markers situated on the endothelial wall. The shear force of 
vessel Blood-flow does significantly weaken microbubble ligand complexes-receptor 
binding complexes. Increasing the ligand density present on the microbubble surface has 
been found to be a reliable method by which to target binding can be enhanced. No further 
improvement in receptor binding is exhibited above a certain ligand concentration (Tinkov 
et al 2009). Supple ligand-microbubble spacer arms are a promising method by which 
endothelial wall receptor binding can be stabilised against shear blood-vessel forces. It has 
been theorised that the formation of the ligand endothelial wall receptor complexes induces 
microbubble core pressurization. The resultant deformation in the shape of the microbubble 
shell produces limited gaseous leakage and wrinkling microbubbles with outward 
protrusions, which enhance adhesion characteristics (Kilbanov et al 1999).  
The laminar flow patterns present in larger vessels may ameliorate the possibility for 
significant target binding. The application of ultrasound beams can deflect circulating 
microbubbles on to the endothelial vessel walls enabling improved contact targeting. This 
property can help overcome the problem of sclerotic plaque targeting in larger vessels and 
the microbubble targeting inflammatory deep venous areas (Dayton et al 1999).  
4. Therapeutic microbubble vectors 
Specificity of drug delivery and targeting is the panacea pharmaceutical technologies. The 
biological barrier forms a worthy barrier to entry of the therapeutic compounds. These 
biological barriers include the cell membrane, capillary endothelium, and blood - brain 
barrier and vessel walls. These barriers can selectively transport molecules of varying 
molecular sizes. Ultrasound targeted microbubble destruction will enable the transport of 2-
3 MDa, 6-8 µm, ~ 9 nm,~100 nm through the cell membrane, capillary endothelium (vessel 
diameter <7 µm), vessel wall diameter ~55 µm) and blood brain barrier respectively 
(Schlicher et al., 2006; Skyba et al., 1998).  
A dichotomy exists between the desired characteristics necessary for the delivery of 
compounds to intracellular target sites. A simple innately lipophilic natured compound will 
preferentially access the intracellular compartment but, lacks the ability to freely transit in 
the aqueous haematological system to the cellular compartment. Uncomplicated hydrophilic 
agents can easily around the circulation, but without the benefit of selective specialised 
transport proteins are unable to enter intracellular compartments. Interiorisation of active 
compounds may be augmented through the application of ultrasound to cell-membrane 
barrier. Small molecular compounds, including polynucleotides and proteins can pass into 
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the intracellular compartment through the process of cavitation when facilitated with 
focused ultrasound. High energy ultrasound cellular damage is an undesirable effect of 
focused high-energy ultrasound. The acoustic cellular damage induced at these energies 
required to induce significant gases cavitation in vitro make this prospect clinically 
unreasonable (O’Brien 2007). 
The application of ultrasound resonance field to microbubbles induces their frequency 
dependent oscillation. Microbubbles destabilisation and destruction can be induced with 
targeted high-energy ultrasound. Local delivery can be achieved through the liberation of 
the active product at the target site with the microbubbles acting cavitation nuclei. 
Significantly lower levels of the ultrasound energy are necessary when used in combination 
with microbubble agents.  
If insonated microbubbles pass in the near vicinity of cellular membranes, the characteristics 
of the cell membranes may be altered and demonstrate the presence of sonopores. Their 
appearance may be the result of the proposed phenomena specific to microbubbles, these 
include microstream swirling, micro-jetting, the impact of enhanced ion-channel 
conductance, the formation of hydrodynamic shock waves or controversially free radical 
formation (12-24)(Miller & Quddus 2000; Miller & Pislaru 2002; Marmottant & Hilgenfeldt 
2003; Barnett 1998; Guzman et al., 2003; Wang et al., 1999; Wei et al., 2004; Juffermans et al., 
2006; Miller & Thomas 1993). There remain dissenters as to the whole validity of the 
cavitation theory, whilst others propose alternative ionic channel conductance mechanisms 
(Lawrie et al., 2003; Bouakaz A et al., 2006).  
Bioactive substances may be able to infiltrate into the intracellular compartment through 
these sonate induced pores. These induced cellular membrane transit pores are transient 
(seconds to minutes) in their nature because of an endogenous vesicle-based healing 
responses resulting in these channels resealing. These healing processes are dependent 
calcium and ATP based processes. Their estimated sizes range from 30-100nm in size up to a 
maximum of a couple of millimetres (Pan et al., 2005). 
It is questionable whether the formation membrane pores results in proportional changes in 
the nuclear membrane. Some studies have found that the viscous cytoplastic nature meant 
that the formation of these pores do not affect the nucleus. In contradiction to this one in 
vivo study has demonstrated that targeted ultrasound microbubble destruction resulted in 
nuclear uptake of rhodamine-labelled (Duvshani-Eshet et al., 2006). 
It has been proposed that the ultrasound focused destruction of microbubbles increases the 
capillary permeability at the cellular microvascular level. The implication is that 
permeability can be enhanced active compounds can be enhanced. The reciprocal 
undesirable effect is that the application of focused-ultrasound microbubble destruction can 
result in local haemorrhage (Tinkov et al., 2009) 
5. Drug loading 
Manipulation to the microbubble formulation alters their physiochemical characteristics 
significantly, particularly the shell volumes and widths. There are four classes of 
microbubble structures with the capacity as gene and drug carriers. Potentially higher drug 
loads can be loaded into acoustically-active lipospheres (shell thickness [triacetin layer 500-
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1000 nm], [soya-bean oil layer 300-700nm]), microcapsules(usually emulsification method, 
shell thickness 50-200 nm) and protein-shelled microbubbles (HSA-shelled microbubbles, 
probe-type sonication method, thickness 200-300 nm) possess larger shell volumes to which 
active products can be embedded. Whereas, Phospholipid-microbubbles (shell thickness 2-3 
nm), because they have smaller shell volumes have better acoustic properties (Tinkov et al., 
2009). 
The most common approach for drug-loading in phospholipid and protein microbubbles is 
for shell surface loading. The loading process of the active agents within the entire volume 
of the shell is appropriate for microcapsules and on occasion protein composite 
microbubbles. 
Microbubble drug coupling can be achieved through a number of the modalities. In essence 
microbubbles are gas-filled colloidal particle, which comprises a surfactant wrapping a 
flexible protein and polymer shell. 
The outer shell surface can be used as a foundation by which active products can be attached. 
Drug compound attachment of the microbubble composite polymer shell can be utilise van-
der-waal, hydrophobic or electrostatic forces. The association of active agents can be achieved 
through the association of smaller secondary shell surface anchor/carrier particles proteins or 
complexation to adhesive human serum albumin molecules. The nucleic acids, DNA and RNA 
can be attached to the outer microbubble shells with charge coupling. 
Physical encapsulation in biodegradable polymeric shells offers the advantage of facilitation 
of the appropriate elimination from the systemic circulation. These biocompatible shells can 
consist of compounds such as gelatin, and may reduce immunogenicity and unfortunately 
ligand affinity.  
Hydrophobic drugs molecules incorporated within can be submerged within the oily layer 
of lipospheres or intercalated between the monolayer of phospholipids. 
A ‘phase-shift’ colloid emulsion vehicle is an elaborate system consisting of a 
perfluoropentane microemulsion system stabilised by biodegradable surfactants. This 
colloid emulsion is then loaded with the active compound possessing the appropriate 
physiochemical properties. The droplet-colloid composition is phase-shifted to bubble form 
through the application of heated sonication (Rapport et al., 2007).  
6. Co-administration drug targeting 
The drug loading of microbubbles is not essential to glean the benefits of their potential 
drug targeting properties. Administration of microbubble agents can be accompanied by the 
active product. Ultrasonic beam application at the target sites may facilitate the entrance of 
otherwise circulating active product into the interstitial compartment and into the 
intracellular compartment. Further study is necessary to study the therapeutic modality of 
this approach (Tinkov et al., 2009).  
7. Targeted microbubble production 
The process production and formulation begins with the identification of an amenable 
disease and correlated target disease specific receptor. A therapeutic mechanism and active 
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compound are prerequisites to ensure the efficacy of any potential enhancement with 
microbubble targeting. Comprehensive understanding of pharmacological, 
pharmacodynamics, physiochemical and dosages are essential to ensure realistic and cost-
effective production of clinically applicable microbubble compounds. The active compounds 
must be amenable to the microbubble formulation process, which in many instances may 
denature and degrade biological compounds (e.g peptide, nucleic acid and monoclonal 
antibodies) and many synthetic compounds. Highly thermodynamic and immunogenical 
components be they active compounds or ligands are unsuitable for incorporation into 
microbubble formulations. For several molecular therapeutic compounds the impact of the 
formulation and manufacture process makes targeted microbubble modalities non-feasible.  
The production process must incorporate uncompromising quality control based on sound 
reproducible manufacturing practices and in-depth understanding of both components and 
the required end-product. 
Complexation of the active products to the shell utilises the relative physiochemical 
characteristics of the shell and the active product. Non-covalent bonding to the shell ensures 
appropriate strength to their loading and for ultrasonic liberation. Electrostatic charged 
albumin and phospholipids can be coupled to charged active products.  
7.1 Phospholipids 
Semi-synthetic flexible phospholipid thin monolayer possesses suitable acoustic properties. 
When present in solution the microbubble the hydrophobic portion orientated internally 
towards the gaseous centre and the electrostatic hydrophilic elements coming in continuity 
with the aqueous solvent. The condensation of the saturated fatty acid chains portions of the 
phospholipids structure imparts integral stability to the gel micelle shells.  
There is a wide spectrum of the phospholipid compositions, including unsaturated fatty 
acid chains. Amalgamation of certain phospholipids and excipients can drastically alter the 
microbubble stability. An example, includes the integration of unsaturated chained 
phospholipids into the shell significantly reduces the stability of the microbubble shells. 
Alternatively, the steric stabilisation can be achieved with the inclusion of PEGylated 
phospholipid. 
Other phospholipid compounds or phospholipid adjuvants impart an extended range of 
characteristics to these microbubble vectors. The inclusion of PEGylated or non-bilayer 
phospholipids can prolong circulation and gene payload transfection, respectively. 
Alteration of the condensed and disordered phase domains within the phospholipid layers 
changes the miscibility of components within the shell, with a result in its characteristics.  
The heterogeneity of constituent components changes the degree of phase separation, which 
itself alters the capacity for drug/ligand loading, stability, and acoustic characteristics. 
Heterogeneity of phase separation can confer desirable characteristics to the microbubble 
formulations. One such advantage imparted by the incorporation of brush moieties is 
through the steric protection they can provide. The major disadvantage is the threat to 
formulation quality, which may be the result of phase separation in the lateral orientation. It 
has been suggested that the degree lateral phase separation may be the limited through 
adjustment of the fabrication process and through manipulation of the shells composition. 
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The condensation state is a crucial in determining the in vivo stability and is reliant upon on 
the temperature. To ensure that an agent has sufficient in vivo stability the physiological 
body temperature must be below the threshold phase-transition temperature (Borden et al., 
2005).  
When considering phospholipid constructs the stability is very dependent upon the 
hydrophobic carbon chain lengths. Longer carbon chained microbubble phospholipid shells 
possess less surface tension and an increased tendency to resist gaseous permeation. 
Increased viscosity with enhanced durability, but reduced acoustic characteristics with 
diminished echogenicity (Duncan P.B. & Needham D. 2004). 
The ideal compromise to ensure optimal phospholipid microbubble stability and the 
existence of the minimal phase-shift characteristics, which are achieved by ensuring the 
equivalence of the various constituents phase-transition temperatures and phospholipid 
fatty-acid residue lengths. Avoidance of unsaturated phospholipid components possessing a 
large degree of conformational liberty would also improve stability. These ‘loose’ 
phospholipids destabilise the order of the otherwise densely packed monolayer. 
Microbubble monolayer destabilising and disorganising abundant surface electrostatic 
charges should also be avoided because they induce electrostatic repulsions within a layer 
orientation (Borden et al., 2006).  
Non-conventional production of the phospholipid can be undertaken using a flow-focused 
method, which encompasses the passage of the inert gaseous core and shell material 
through a fine nozzled device and into a water reservoir.  
7.2 Polymeric 
In terms of polymeric microcapsule formulations characteristics are dependent upon 
material biocompatibility polymeric component weight, which possesses a direct relation to 
the shell thickness. Variability to the polymer constituents influences the stability, 
echogenic, time to destruction and acoustic characteristics (Forsberg et al., 2004).  
Inappropriate selection of the incorporated of Proteinaceous excipients into the microbubble 
shell can also embarrass the functional stability of therapeutic microbubble formulations. 
Exposural factors, which may disrupt the self-association forces between shell components, 
which must be mitigated against, include heat and free-radicals. Adhesive shell building 
factors include thiol-rich proteins including HSA. These forces are imparted through the 
sonication of the shell constituents’ results in intensive cavitation and free-radical 
production, which result in the production of HSA linking thiol bridges. These bridges can 
also be formed with the addition of glutaraldehyde and formaldehyde during the shell 
formation process (Tinkov et al., 2009).  
7.3 Mechanical agitation 
The most frequently utilised method for the production of acoustically active lipsomes and 
phospholipid-shelled microbubbles. The initial phase of the process involves the formation 
of a thin hydrated phospholipid sheet, which is then either infiltrated with an alcoholic 
component or phase inverted by an alternate approach. A gaseous component is then 
pressed in the space above the liposomal dispersion and then agitated at least several 
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thousand oscillations every second. Loading of the active agents can take place at initial 
microbubble production or after this second gaseous core forming stage. To ensure a 
predictable desire loading pattern it essential to take steps to ensure loading of the active 
molecular compounds are bound to the liposomal shell instead of encapsulated within the 
water soluble liposomal centre (Tinkov et al., 2009). 
The key to the production of the acoustically active liposomes revolves around the 
production of the appropriate micro-emulsion. This can be undertaken through the 
combination of the perpetual aqueous phase and injectable oil phase. Suitable constituents 
of the injectable oil phase include castor or triacetin oil. Successful emulsion formation 
requires the incorporation of co-solubilizers, such as synthetic block copolymers, because of 
the defoaming characteristics of the oil phase. The adequately lipophilic agent can then be 
dissolved and remain persistently encapsulated within the oily phase and acoustically active 
liposomes (Fang et al 2007)  
This versatile modus operandi for the production of therapeutic microbubbles is 
advantageous when integrating delicate targeting ligands and drugs molecules. Successful 
utilisation of this drug-loading approach requires meticulous control of important variable 
production parameters. Components concentrations, viscosity, Agitation time and 
temperature must be all thoroughly controlled to ensure predictable characteristics.  
7.4 Emulsification 
Some phospholipid-shelled microbubble and many polymer shelled microcapsule 
formulations are produced with this oil-in-water freeze-drying emulsification production 
method. Some of the commonly used later generations of contrast enhanced ultrasound 
agents have been manufactured in this manner. The inner emulsion phase consists of a 
volatile solid compound (such as camphor), an organic solvent phase, which has the 
characteristic of being lyophilizable water-immiscibility and polymeric shell material. The 
water-water-insoluble benzene compound based solvents, such as toluene or p-xylene. The 
polymeric shell material consists of compounds similar to the highly biodegradable and 
biocompatibile co-polymer poly-lactide-co-glycolide (PLGA). The emulsion matrix is the 
residual after the removal of the volatile aqueous and organic phases remaining after the 
freeze-drying process. The gaseous cores are formed after reconstitution of the gaseous vial 
and emulsion matrix with the injection solvent medium. Coverage of these microbubbles 
with gelatin or albumin compounds included in the aqueous phase of this emulsification 
production method may significantly improve their biocompatibility profile (Schneider et 
al., 1991; El-Sherif et al, 2003; Short 2005).  
Lipophilic active products can be easily accommodated within organic emulsion phase of 
polymeric shelled microbubbles compounds. Water-soluble drugs and biological agents can 
be accommodated in these formulations through encapsulation. Incorporation of 
hydrophilic compounds within the mixed-phase emulsion is undertaken through their 
dispersion within the shell containing the organic phase. The next step of the process 
involves the production of a double emulsion, which consists of water in organic in water 
emulsion. The lypophilization of the double emulsion is the final synthetic mechanism 
resulting in hollow shell drug-loaded microbubbles. The important factors that need to be 
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controlled include the emulsion droplet sizes; quantity and molecular weight of the shell 
material monomers (Tinkov et al, 2009).  
7.5 Probe-type sonication 
Low frequency and high intensity ultrasound is the commonest technique for the 
production of protein-shelled microbubbles and less commonly phospholipid microbubbles. 
Ultrasound induces exuberant convection streams to disperse the inert gaseous phase into 
the aqueous phase and produces the microbubble gaseous core. The process generates free 
radicals and temperature rises in excess of seventy degrees centigrade, which itself produces 
insoluble-shell microbubble shells. The proteins can be denatured with unveiling of their 
thiol-groups with the subsequent formation of covalent and non-covalent bridging bonds. 
Phospholipid microbubbles do not benefit from higher temperatures as their exceeding their 
phase-transition temperature can be deleterious to the formulation.  
The most commonly utilised shell building component was HSA because of its exceptional 
affinity to a wide spectrum of active agents, including nucleic acid products. Drug loading 
to only the outer shell can be undertaken with the cell surface loading approach. This 
involves the incubation of the active consignment compounds to composed microbubbles. 
The disadvantage of this approach is a relatively low concentration of active product can be 
achieved through this process of surface absorption. This limitation can be overcome by the 
inclusion of the compound throughout the depth of the shell. This can be achieved through 
the application of sonication to the shell active product mixture prior to the microbubble 
formulation. Fragile active compounds may not be amenable to the entire shell loading 
approach as they will be damaged by the harsh cavitation and chemical and thermal 
stresses.  
7.6 Spray-drying method 
This versatile approach is essentially the formation of hollow particles through a spray-
drying process. Encapsulation with the spraying technique is commonly utilised for the 
production conventional microbubbles. It provides an opportunity for a reliable method by 
which drug-loaded polymeric- and protein-microbubbles can be manufactured. This spray-
drying method provides drug volume loading, a stable dried product and a final 
composition produced in favourable conditions.  
Phospholipid-, protein- and polymer- microbubble formation utilises volatile ammonium 
derivatives and organic liquids (e.g. halogenated hydrocarbons) to induce pores and cavities 
in spray-dried particles. The commonly utilised HSA components of microbubble shells can 
be thermally stabilised and undergo chemical, but not free-radical cross- processes. The 
premise of this approach is the application of an evaporation process to a solvent mixture 
containing the dissolved shell material. The resultant saturation of the air-water interface 
with solvent-mixture forms an elastic film layer. On the droplets surface the shell 
components within the film solidifies, whilst the associated solvent completely evaporates. 
The particle formation is determined by the pressure induced fluid conversion into solid. 
The optimal acoustic characteristics are exhibited by microbubbles with the largest possible 
core cavity volumes. This spray-drying technique does not result in a uniform population of 
microbubble particle characteristics. The core cavity sizes can vary dramatically from 
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exceptionally large cavities with fragile shells to multiple small voids (Porter 1997; 
Lentacker et al., 2007).  
8. Stability 
The shell is fundamental for microbubble stability is maintains the integrity of the gaseous 
core by preventing the leaching of the gaseous core and minimising interface tensions. There 
is a complex gaseous balance reached between the solvent saturated gases and the gaseous 
core content. The passage of gas occurs from the core into the plasma solvent and 
simultaneously from the solvent into the gaseous core. This continues until the gaseous 
partial pressure equilibrium has been achieved. When the net gaseous movement is static 
the equilibrium osmotic gradient is zero. The aqueous insoluble Perfluorocarbon 
microbubbles vivo have negative osmotic gradient, so initially tend to increase in size 
because the net passage of aqueous dissolved gases into the gaseous core. Formulation 
techniques to improve stability include the incorporation of mixed gaseous cores, such core 
have been termed osmotically stabilized. Specifically engineered shells may reduce the 
degree of gaseous passage, but will be unlikely completely ameliorate it. Alteration of the 
gaseous core constituents will prove a more robust modification (Tinkov et al., 2009).  
Air-filled microbubbles consisting of proteineous shells possess inferior echogenicity 
characteristics than fluorinated gas core microbubbles. The water insoluble perfluorobutane 
and sulphur hexafluoride consisting gaseous core microbubbles confer some superior 
properties to more advanced microbubble generations. Perfluorocarbon containing third 
generation microbubbles are disadvantaged by their tendency to absorb blood containing 
gases resulting in an inconsistent size profile and potentially reduced stability due to 
swelling. Perfluorocarbon and nitrogen mixtures may fare better and possess inherently 
superior pharmacodynamics properties (Tinkov et al 2009).  
9. Quality control 
Quality assurance requires a detailed understanding of microbubble properties. The 
formulation characteristics, which complicate analysis, revolve around the dynamic nature 
of microbubbles and their delicate quiescent phases. Their complicated characteristics 
include their unpredictable buoyancy and excessive sensitivity to shear-stress, pressure, 
temperature. These drug-loaded microbubbles are relatively complex composite mixture of 
molecular interacting structures, which can behave in a broad manner at any one time. 
Despite many of these unique properties many conventional assays can be utilised in an 
efficacious manner. Specific analytic tests are necessary to characterise therapeutic 
microbubble destructibility and echogenicity (Tinkov et al 2009).  
9.1 Size 
The terminological dogma underlying therapeutic microbubbles dictates size limitations of 
between 500 nm and 1µm in size. This size ranges enables optimal compromise between 
drug-loading in the gaseous core and echo signal. Nanobubble preparations have a greater 
predilection to take advantage of the permeability and retention effect. Nanoparticles more 
easily cross leaky capillary walls. Nanobubble units can have a tendency to coalescence into 
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a microbubble conformation, thus ameliorating this advantageous property of the smaller 
bubbles (Tinkov et al 2009).  
Acoustic activity, pharmacodynamics and pharmacokinetics of microbubble preparations 
are highly dependent upon their size distrubtion. A Broad, mult- or bimodal distribution 
rather than a more conventional normal distributions have been found. The upper size 
limit should be between 5 to 10µm to enable safe clearance through the pulmonary 
vasculture. The size distribution can be sized and calculated by using electromagnetic 
impedance field calculation. As the particles pass through the ‘coulter counter’s’ 
miniscule apertures located between two the complementary electrode the reading are 
produced. The detection and measurement of microbubble shadows cast as microbubble 
particles passage before a narrow uniform light source, is termed the ‘light obscuration’ 
method. The size range of this technique is has a maximum size tolerance of 400µm and 
requires low concentrations to be accurate. Laser diffraction approach can measure in the 
presence of high concentrations, is unaffected by buoyancy and can accurately assess any 
population distribution. Its particle size tolerance is 40-2 mm and requires 
calibration/optimisation for individual compounds. The dynamic light scattering method 
relies upon the ‘Brownian motion of particles’ is seldom utilised due its unreliability 
(Tinkov et al 2009).  
9.2 Zeta potential  
The zeta potential has important ramifications to both the intrinsic physiochemical 
characteristics of microbubble formulations and molecular pharmacokinetics. The active-
product loading capacity, stability of the colloidal dispersion and the interaction with the 
endothelial cell wall properties can be usefully represented by the zeta potential behaviour. 
Preferable zeta potentials may significantly extend capillary retention time duration (Fisher 
et al., 2002).  
The electrophoretic mobility can be determined by the degree of laser light scattering, which 
results from particle oscillation induced by an alternating electrical field. Using 
mathematical modelling the electrophoretic potential be translated into the zeta potential. 
The accuracy and precision of this presumptive calculation can be compromised by the 
inherent characteristics of microbubbles. The convection associated buoyancy compromises 
the reproducibility of original electrophoretic observations. Several environmental, 
physiochemical and electrochemical can affect the calculated zeta potential measurements 
(Tinkov et al 2009).  
9.3 Mechanical properties 
Critical to the modality of microbubbles is their characteristic acoustic behaviour on the 
application of an ultrasounic field. This behaviour is dictated by the shell characteristics. 
Advanced in the field of dynamic imaging has enabled the robust characterisation of 
ultrasound manipulated microbubbles. 
The shell hardness plays a disproportionally large role in the determination of the ultrasonic 
threshold energy microbubble cracking threshold. Upon reaching their reaching their 
cracking threshold the encapsulating shell wall ruptures and the gaseous bubble is released 
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instantaneously leaving a partially maintained shell. Harder shells require in the order of 
twice to twenty-fold the ultrasonic energy to rupture and liberate is payload, in comparison 
to softer shelled formulations. These necessarily high energy levels and more pronounced 
harder-shell microbubble oscillations may have a deleterious effect upon the adjacent cells 
(Postma et al., 2004; Tinkov et al., 2009).  
Soft more pliable shells, such as phospholipid shell components oscillate through the 
process of expansion and contraction. With the expansions lipid aggregates are expelled and 
then reseals. Significantly lower ultrasonic energies are necessary to rupture softer shells 
(Sboros et al., 2006; Tinkov et al., 2009)  
9.4 Lateral phase separation 
Microbubble shells can be significantly compromised by the phenomenon of phase 
separation. The molecular findings demonstrated within the shell during lateral phase-shift 
are an uneven distribution of constituents. The differentials in inherent forces include 
heterogeneous electrostatic binding and steric-shielding binding forces. Quality assurance 
methods are essential to ensure microbubble stability. Fluorescent dye tagged microbubble 
laser scanning confocal microscopy can employed to characterise the quality of dispersion 
and drug-loading (Borden et al., 2006).  
9.5 Chemical integrity  
Novel and broad characterisation techniques are necessary to ensure quality control of 
payload compounds incorporated within microbubble formulations.  
Reversed-phase and normal-phase liquid chromatography are useful tools for quality 
assurance analysis of smaller molecular therapeutic compounds and small phospholipid 
compounds respectively (Lentacker et al., 2006; Hvattum et al., 2006).  
10. Safety 
There is relatively little clinical experience of the microbubble agents as a result the extent 
and spectrum of adverse events has not yet completely revealed themselves. Thus far, the 
clinical use of these agents as largely contrast ultrasound agents has proven to be safe. The 
complicity of the therapeutic adjuncts will probably introduce further adverse effects.  
Myocardial exposure to microbubble agents may induce a physiological response of 
premature cardiac contractions. Microvascular damage, pectechial haemorrhage, free radical 
damage and single strand DNA fractures are also postulated side-effect of the focused 
ultrasound microbubble destruction process. In clinical practice these complications have 
been seldom encountered.  
In regards to the reasonable ultrasound energies feasible for focused therapeutic 
ultrasound microbubble destruction, ‘the principle of as low as reasonably achievable’ has 
been deemed appropriate by radiological committee guidelines. For clinical ultrasound of 
microbubble agents the accepted safe mechanical index parameters are 0.05 to 0.5. For 
harmonic and non-harmonic clinical imaging modalities exceeding the mechanical index 
of 0.5 would result in microbubble destruction. The American Food and Drug 
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Administration (FDA) have set the maximum accepted mechanical index tolerance of 1.9 
(Tinkov et al., 2009). 
10.1 Immunogenicity 
Although microbubbles themselves are not immunogenic, the incorporation of targeted 
ligands to their shells does render them immunogenic. Immunoreactive components are 
desirable to target delivery, but, undesirable for ability to attract unwanted immunological 
attention whilst in transit to the target site.  
Conventional exposed spacer-linked or directly linked ligands loaded upon the gaseous 
microbubble cores may be inappropriately degraded or trigger an aggressive detrimental 
immunology response. Buried ligands within an overbrushed grafted polymeric-PEG layer 
may enable the camouflage of these immunoreactive elements. This stealth layer can then be 
unveiled and the immunoreactive layer underneath revealed with the application of focused 
ultrasound beam. The ultrasonic waves push the microbubbles towards the vessel walls and 
the polymer sheath is unbrushed and enables ligand binding to the specific receptor 
targeting sites. The caveat of these stealth particle modifications is reduced target receptor 
site affinity (Kilbanov et al., 1999).  
11. Gene-loading microbubbles 
Gene-therapies have proven an intriguing, but nonetheless frustrating proposition. Their 
potentially enduring therapeutic promise has been slighted by some critical inherent 
deficiencies. The absence of any effective conventional carriers has hindered the 
progression of more widely clinically applicable nucleic acid therapeutic options. The 
essential criteria an advanced gene carrier must possess an exceptional safety profile. The 
carriage of their genetic payload must be hostile and protect it from the otherwise 
deleterious effects of native enzymes, immunological elements and pharmacokinetic 
elimination. The aim is the controlled and timely liberation of the active agent followed by 
appropriate transfection of the target cells. Transfection is mediated by attenuated 
viruses, thus rendered incapable of replication and instigating disease. Amongst critics of 
gene-therapy options typical concerns over safety exist as with non-microbubble 
preparations. These safety concerns pertain to the risks of genetic mutations, pathogenesis 
and immunological reactions. Work utilising non-viral vectors aimed at excluding these 
viron-vector related risks has not yielded practical or efficacious alternatives. Alternative 
delivery systems investigated include microbubble, lipoplexes, electroporation and 
microinjection.  
Genetic therapy delivery mediated through microbubble formulations is widely considered 
to be a safe prospect. The enhancement in transfected genetic material quantities is 
significant. In vitro models have demonstrated transfection magnitiude enhancement rates 
of 10-3,000 fold in comparison to naked plasmid DNA constructs alone. Despite the 
observation under in vivo conditions, which have demonstrated 1,000 fold transfection 
improvement, true proven in vivo transfection enhancement remains elusive. Serum 
nucleases are pose a significant risk upon naked and viron loaded nucleic acid compounds. 
The shielding effect of microbubbles has been proposed in microbubble constructs loaded 
with adenovirus-associated microbubbles (Tinkov et al., 2009).  
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Unlike other therapeutic opportunities the response to therapy rarely correlates with the 
quantity delivered. It is essential however, to deliver a threshold quantity to the 
appropriate area. The limited surface absorption binding capacity of plasmid DNA to 
produce maximally loaded gene loaded microbubble is in the order of approximately 
0.001-0.005 pg/µm2. Adjuvants can be utilised to increase the gene binding and loading 
properties. These include the use dipalmitoylphosphatidylethanolamine (DPPE) 
containing phospholipid microbubbles, which have a higher binding capacity to plasmid 
DNA. Layer-by-layer technique with poly-L-lysine may enable pDNA packing to decimal 
points higher than conventional microbubble loading. The absorbed loading of genes on 
to albumin microbubbles has been found not to enhance pDNA loading. Utilising a 
formulation approach a greater than 200-fold loading to entire shell volume has been 
reported. More recent developments are secondary-carriers associated microbubbles and 
the active nucleic acid components. These constitute nanoparticles, polyplexes, liposomes 
and lipoplexes. They have multiple functions, including enhancement of the transfection 
and microbubble strong shell attachment to the microbubble shell with improved loading 
capacity. They function through the condensation of large DNA molecules, thus 
protecting them from the action of serum nucleases. Entrance into the intracellular 
compartment involves both endocytosis and pinocytosis (Frenkel et al., 2002; Tinkov et al., 
2009). 
In vivo microbubble transfection delivery studies have been undertaken in organ systems 
already validated for diagnostic contrast ultrasonography. Vascular paradigms are 
particular relevant to study therapeutic microbubble compounds. Numerous pathological 
vascular paradigms have indicated that the duration of action varies from condensed 
intensive therapeutic windows to the extremes of a month. No meaningful conclusions can 
be drawn from study of these gene-therapy microbubble therapies for atherosclerotic or 
intimal disease. Ultrasound induced sonoporation and of the microbubble containing 
genetic-material enables delivery into the cytoplastic compartment. Nanobubble delivery 
does not seem to enhance entry into the nuclear compartment resulting in its 
deactivation/destruction prior to activity (Newman & Bettinger 2007; Liu et al., 2006; Unger 
et al., 2006).  
Elucidation of formulation, pharmacodynamics and pharmacokinetic principles is necessary 
to definitively ascertain the modality of this novel disease-specific therapeutic option. 
Establishing such studies are complicated by the absence of standardised models with 
comparable measurable parameters. Also more modern genetic therapy incorporated 
microbubble formulations have not been studied to the same extent as co-administration 
preparations. This leaves the door ajar for more modern formulations fulfilling their yet 
unrealised potential (Tinkov et al., 2009)  
12. Conclusion 
Safe in vivo utilisation of microbubble contrast enhanced ultrasound agents is well 
established and validated. The idea of directly translating microbubble into routine used 
therapeutic treatments is oversimplification of the challenge ahead. The premise of 
diagnostic microbubble is with low administrated doses to produce a sustained and clearly 
visible echogenic signal. Whereas, with therapeutic microbubbles the all the associated 
paradigm variables still remain too uncertain. The quantities of both ultrasonographic 
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energy and microbubble dosage are many magnitudes greater, which imparts numerous 
complications. The most serious of these is significant unintentional tissue damage related to 
cavitation-inducing ultrasound beams. A pattern of cellular damage has been demonstrated 
on myocardial tissue between the upper safe ultrasonic energy limit and 2.5 times of this 
limit. Such a degree of irreversible cellular destruction will prove detrimental to organ 
function and subsequently result in significant morbidity. Despite these concerns, it has 
been proven that efficacious microbubble therapeutics used at the effective dosages with 
safely ultrasonography energies.  
Further studies on all aspects of formulation, production and trials of therapeutic 
microbubbles are necessary as a precursor to establishing these agents as realistic 
therapeutic options. The promise in their therapeutic role may lie as co-administration 
agents to optimise selective uptake of the active agents. Therapeutic microbubbles may 
prove the ‘missing-link’ in fixing the inherent shortfalls of promising therapies, particularly 
in reference to gene therapy.  
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